152 related articles for article (PubMed ID: 36240474)
21. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
22. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
Brooks RA; Tritchler DS; Darcy KM; Lankes HA; Salani R; Sperduto P; Guntupalli S; DiSilvestro P; Kesterson J; Olawaiye AB; Moxley K; Waggoner S; Santin A; Rader JS; Kizer NT; Thaker PH; Powell MA; Mutch DG; Birrer MJ; Goodfellow PJ
Gynecol Oncol; 2019 May; 153(2):335-342. PubMed ID: 30827726
[TBL] [Abstract][Full Text] [Related]
23. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
24. Nodal staging in high and high-intermediate risk endometrial cancer surgery: Which role in the molecular classification era?
Massobrio R; Novara L; Mancarella M; Pace L; Giorgi M; Pascotto M; Campigotto B; Fuso L; Sgro LG; Bounous VE; Ferrero A
J Gynecol Obstet Hum Reprod; 2024 Apr; 53(7):102787. PubMed ID: 38626819
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
26. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.
Jamieson A; Vermij L; Kramer CJH; Jobsen JJ; Jürgemlienk-Schulz I; Lutgens L; Mens JW; Haverkort MAD; Slot A; Nout RA; Oosting J; Carlson J; Howitt BE; Ip PPC; Lax SF; McCluggage WG; Singh N; McAlpine JN; Creutzberg CL; Horeweg N; Gilks CB; Bosse T
Clin Cancer Res; 2023 Dec; 29(23):4949-4957. PubMed ID: 37773079
[TBL] [Abstract][Full Text] [Related]
27. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.
Creutzberg CL; Nout RA; Lybeert ML; Wárlám-Rodenhuis CC; Jobsen JJ; Mens JW; Lutgens LC; Pras E; van de Poll-Franse LV; van Putten WL;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e631-8. PubMed ID: 21640520
[TBL] [Abstract][Full Text] [Related]
28. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
29. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
[TBL] [Abstract][Full Text] [Related]
30. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Jeske YW; Ali S; Byron SA; Gao F; Mannel RS; Ghebre RG; DiSilvestro PA; Lele SB; Pearl ML; Schmidt AP; Lankes HA; Ramirez NC; Rasty G; Powell M; Goodfellow PJ; Pollock PM
Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
Beavis AL; Yen TT; Stone RL; Wethington SL; Carr C; Son J; Chambers L; Michener CM; Ricci S; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan AN; Jager LR; Fader AN
Gynecol Oncol; 2020 Mar; 156(3):568-574. PubMed ID: 31948730
[TBL] [Abstract][Full Text] [Related]
32. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
[TBL] [Abstract][Full Text] [Related]
33. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.
Bishop EA; Java JJ; Moore KN; Walker JL
Int J Gynecol Cancer; 2017 May; 27(4):730-737. PubMed ID: 28399028
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
Nasioudis D; Byrne M; Ko EM; Giuntoli RL; Haggerty AF; Cory L; Kim SH; Morgan MA; Latif NA
Gynecol Oncol; 2021 Jun; 161(3):705-709. PubMed ID: 33771397
[TBL] [Abstract][Full Text] [Related]
35. Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center.
Tai YJ; Hsu HC; Chiang YC; Chen YL; Chen CA; Cheng WF
Int J Environ Res Public Health; 2019 Jul; 16(14):. PubMed ID: 31323767
[TBL] [Abstract][Full Text] [Related]
36. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
37. Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.
Bateman NW; Dubil EA; Wang G; Hood BL; Oliver JM; Litzi TA; Gist GD; Mitchell DA; Blanton B; Phippen NT; Tian C; Zahn CM; Cohn DE; Havrilesky LJ; Berchuck A; Shriver CD; Darcy KM; Hamilton CA; Conrads TP; Maxwell GL
Cancer; 2017 Oct; 123(20):4004-4012. PubMed ID: 28654152
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).
Chen JR; Chang TC; Fu HC; Lau HY; Chen IH; Ke YM; Liang YL; Chiang AJ; Huang CY; Chen YC; Hong MK; Wang YC; Huang KF; Hsiao SM; Wang PH
Medicine (Baltimore); 2016 Apr; 95(15):e3330. PubMed ID: 27082583
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant Chemotherapy versus Radiotherapy in High-risk, Early-stage Endometrioid Endometrial Carcinoma.
Wu M; Yang YN; Huang YH; Cai J; He XQ; Wang ZH
Curr Med Sci; 2022 Feb; 42(1):185-191. PubMed ID: 34669113
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
